Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in routine clinical practice. Eligible patients will be followed for approximately 15 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Progression-free survival, defined as time from first administration of first-line therapy to documented disease progression | approximately 6 years | |
| Safety: Incidence of adverse events | approximately 6 years |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival, defined as time from first administration of first-line therapy to documented death | approximately 6 years | |
| Objective response rate, defined as percentage of patients with complete or partial response according to local assessments | approximately 6 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer undergoing first-line treatment with chemotherapy and Avastin
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal United Hospital; Oncology Department | Bath | BA1 3NG | United Kingdom | |||
| City Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31780570 | Derived | Hall M, Bertelli G, Li L, Green C, Chan S, Yeoh CC, Hasan J, Jones R, Ograbek A, Perren TJ. Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. Int J Gynecol Cancer. 2020 Feb;30(2):213-220. doi: 10.1136/ijgc-2019-000512. Epub 2019 Nov 27. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Quality of life: EQ-5D/EORTC questionnaires | approximately 6 years |
| Dosage/schedule/duration of Avastin therapy | approximately 6 years |
| Composition of first-line chemotherapy regimens: drugs/dosage/duration | approximately 6 years |
| Birmingham |
| B18 7QH |
| United Kingdom |
| Bradford Royal Infirmary; Oncology Department | Bradford | BD9 6RJ | United Kingdom |
| Bristol Haematology and Oncology Centre | Bristol | BS2 8ED | United Kingdom |
| Queen's Hospital; Oncology Department | Burton-on-Trent | DE13 0RB | United Kingdom |
| Essex County Hospital | Colchester | CO3 3NB | United Kingdom |
| Eastborne District General Hospital | Eastbourne | BN21 2UD | United Kingdom |
| Wonford Hospital; Oncology Department | Exeter | EX2 5DW | United Kingdom |
| Royal Surrey County Hospital | Guildford | GU2 7XX | United Kingdom |
| Ipswich Hospital | Ipswich | IP4 5PD | United Kingdom |
| Airedale General Hospital; Research Office Ward 12 | Keighley | BD20 6TD | United Kingdom |
| St James University Hospital | Leeds | LS9 7TF | United Kingdom |
| Royal Marsden Hospital - London | London | SW3 6JJ | United Kingdom |
| Maidstone Hospital; Kent Oncology Centre | Maidstone | ME16 0FS | United Kingdom |
| Christie Hospital Nhs Trust; Medical Oncology | Manchester | M2O 4BX | United Kingdom |
| The Clatterbridge Cancer Centre NHS Foundation Trust | Metropolitan Borough of Wirral | L63 4JY | United Kingdom |
| The James Cook University Hospital | Middlesbrough | TS4 3BW | United Kingdom |
| Mount Vernon Hospital | Middlesex | HA6 2RN | United Kingdom |
| St Mary's Hospital | Newport | PO30 5TG | United Kingdom |
| City Campus; Academic Unit of Oncology | Nottingham | NG5 1PB | United Kingdom |
| Queen Alexandra Hospital; Portsmouth Haematology & Oncology Centre, Level B | Portsmouth | PO6 3LY | United Kingdom |
| Weston Park Hospital; Cancer Clinical Trials Centre | Sheffield | S10 2SJ | United Kingdom |
| Southampton General Hospital | Southampton | SO16 6YD | United Kingdom |
| City General Hospital | Stoke-on-Trent | ST4 6QG | United Kingdom |
| The Royal Marsden Hospital | Sutton | SM2 5PT | United Kingdom |
| Singleton Hospital; Oncology | Swansea | SA2 8QA | United Kingdom |
| Torbay Hospital; Oncology Department | Torquay | TQ27AA | United Kingdom |
| Royal Cornwall Hospital | Truro | TR1 3LQ | United Kingdom |
| New Cross Hospital; Deansley Centre | Wolverhampton | WV10 0QP | United Kingdom |
| The York Hospital | York | YO31 8HE | United Kingdom |
| ID | Term |
|---|---|
| D010051 | Ovarian Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |
Not provided
Not provided